Ocugen Q2 2026 earnings: Financing boosts cash while net loss widens

Ocugen (NASDAQ: OCGN) reported second-quarter 2026 collaborative-arrangement revenue of $1.49 million, up 8.4% from $1.37 million a year earlier, while basic and diluted net loss per share widened to $0.07 from $0.05. Net loss increased to $24.9 million as research spending and below-the-line expenses rose, although a convertible-note offering lifted cash resources to $100.4 million and extended the company’s stated runway into 2028.

Core financial results

Revenue increased by approximately $0.1 million, but remained small relative to Ocugen’s operating cost base. Total operating expenses rose 18.2%, led by a 27.2% increase in research and development spending as the company advanced three retinal gene-therapy programs.

The increase in weighted-average shares helped limit the per-share deterioration relative to the larger percentage increase in net loss.

Pipeline and business progress

Ocugen’s principal operational developments involved OCU410, OCU410ST, and OCU400. The programs reached regulatory, enrollment, or manufacturing milestones during the quarter, with the next major data readouts scheduled for the first half of 2027.

The OCU410 Phase 3 plan is supported by 12-month Phase 2 data showing a statistically significant 31% reduction in geographic-atrophy lesion growth versus control at the selected dose in the specified lesion-size population. RMAT designation makes the program eligible for regulatory mechanisms including priority review and accelerated approval, but it does not guarantee either outcome.

Ocugen also signed a binding term sheet with Roots Pharmaceutical and strategic partner Al-Dhow International Holding to negotiate an exclusive OCU400 license covering the Middle East and North Africa. The proposed economics include up to $255 million in sales milestones, a 22% royalty on net sales, and an unspecified upfront payment. Because the parties are still negotiating the license, these terms should not be treated as recognized or guaranteed revenue.

Profitability, liquidity, and the balance sheet

Cash, cash equivalents, and restricted cash reached $100.4 million at June 30, 2026, compared with $32.2 million at March 31. The increase followed the issuance of $130.0 million in 6.75% convertible senior notes due 2034, which generated approximately $112.5 million in net proceeds.

Ocugen used approximately $32.7 million of the proceeds to repay its Avenue Capital loan, removing debt carrying a 12.25% interest rate. Management said the remaining liquidity extends the company’s cash runway into 2028.

The financing also made the balance sheet more complex. At quarter-end, Ocugen reported $82.4 million of convertible notes and a $33.7 million derivative liability within current liabilities. Total current liabilities were $133.1 million, compared with current assets of $106.7 million, while stockholders’ deficit increased to $16.6 million from $12.2 million at the end of 2025.

Financing strengthened liquidity but increased below-the-line pressure

Ocugen’s operating loss widened by $2.6 million year over year, but its net loss widened by $10.1 million. The difference came from total other expense, which increased to $8.4 million from $0.9 million.

The quarter included $4.5 million of interest expense, up from $1.3 million, along with a $2.4 million loss on debt extinguishment and a $1.9 million loss from the change in fair value of the derivative liability. These items show the trade-off created during the quarter: the financing materially increased available cash and removed higher-rate debt, but financing-related accounting and interest costs placed additional pressure on reported earnings.

Clinical and liquidity outlook

Ocugen did not provide revenue or earnings guidance, but it reaffirmed several quantitative clinical and liquidity milestones. The main near-term focus is execution through the first half of 2027, when two late-stage programs are expected to report top-line data.

Recent insider transactions

The supplied transaction detail contains six reported insider transactions over the last two years, including three purchases and no sales. However, the accompanying six-month aggregate panel showed zero purchases and zero sales, which conflicts with the June 2026 CFO purchase listed in the detailed records.

The records do not provide enough consistent information to draw conclusions about overall insider sentiment.

Risks investors need to watch

• Clinical and regulatory execution: The next major value-driving events depend on OCU400 and OCU410ST data in 2027 and successful initiation of OCU410 Phase 3. Earlier-stage results may not predict registrational outcomes or regulatory decisions.
• High spending relative to current revenue: Quarterly operating expenses of $17.9 million substantially exceeded collaborative-arrangement revenue of $1.5 million. The stated runway into 2028 depends on future spending and development execution.
• Financing and accounting volatility: Convertible notes, interest costs, and changes in the derivative liability’s fair value can cause net results to move more sharply than operating expenses.
• Balance-sheet pressure: Current liabilities exceeded current assets at quarter-end, and Ocugen reported a stockholders’ deficit despite the financing-related increase in cash.
• Partnering uncertainty: The proposed MENA license remains subject to negotiation, while the disclosed $255 million opportunity consists of contingent sales milestones rather than committed proceeds.

Summary

Ocugen’s second-quarter results reflected a company funding an increasingly late-stage clinical pipeline rather than generating substantial operating revenue. Higher research spending and financing-related expenses widened the loss, while the convertible-note offering materially strengthened liquidity and extended the stated runway into 2028. Execution of the OCU410 Phase 3 launch and the OCU400 and OCU410ST data readouts in the first half of 2027 are the principal milestones to monitor.

Find out more